A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC)

Investigational New Drugs

Volumn 24, Issue 4, 2006, Pages 343-346

  Bekaii Saab, Tanios S ^a,b   Mortazavi, Amir ^a   Hicks, Lee G ^c   Zalupski, Mark ^d   Pelley, Robert J ^e   Chan, Kenneth K ^b   Kraut, Eric H ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c CENTRAL BAPTIST HOSPITAL   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Chloroquinoxaline Sulfonamide; Colon cancer; Investigational drug; Metastatic

Indexed keywords

5 CHLOROSULFAQUINOXALINE; FLUOROURACIL; HALIDE; IRINOTECAN;

ADULT; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ATAXIA; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONSTIPATION; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG TREATMENT FAILURE; FATIGUE; FEMALE; FEVER; FLUSHING; HEADACHE; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; METASTASIS; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; UNITED STATES; URTICARIA; VIRUS REACTIVATION;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; NEOPLASM METASTASIS; QUINOXALINES; SULFANILAMIDES;

EID: 33646529457     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-005-4827-3     Document Type: Article

References (14)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. CA Cancer J Clin 55(1):10-30, 2005
2. Pazdur R., Coia LR, Wagman LD, Ayoub JP: Colorectal and Anal Cancers. In: Cancer Management: A Mulitidisciplinary Approach. Third Edition. Ed. By Pazdur R, Coia L, Hoskins WJ, Wagman LD. PRRR, Huntington NY, 1999
3. Tong WP, Hartshorn J, Mathews LA: Chloroquinoxaline sulfonamide, investigational drug brochure. National Cancer Institute, Division of Cancer treatment, 1987
4. Branda RF, McCormack JJ, Perlmutter CA: Cellular pharmacology of chloroquinoxaline sulfonamide and a related compound in murine B16 melanoma cells. Biochem Pharmacol. 37(23):4557-4564, 1988
5. Gao H, Yamasaki EF, Chan KK, Shen LL, Snapka RM: Chloroquinoxaline sulfonamide (NSC 339004) is a topoisomerase IIa/β poision. Cancer Res 60: 5937-5940, 2000
6. Hickey R, Schiffer J, Wei Y, Malkas L: DNA synthesis is differentially affectd by the drugs mebarone and chloroquinoxaline. Proc Am Assoc Cancer Res 34:352, 1993
7. Branda RF, Moore AL, McCormack JJ: Immunosuppressive properties of chloroquinoxaline sulfonamide. Biochem Pharmacol 38: 3521-3526, 1989
8. Rigas JR, Tong WP, Kris MG, Orazem JP, Young CW, Warrell RP Jr: Phase I clinical and pharmacological study of chloroquinoxaline sulfonamide. Cancer Res 52(23):6619-6623, 1992
9. Conley BA, O'Hara S, Wu S, Melink TJ, Parnes H, Pardoe E, Egorin MJ, Van Echo DA: Phase I trial of chloroguinoxaline sulfonamide, with correlation of its pharmacokinetics and pharmacodynamics. Cancer Chemother Pharmacol 37(1-2):139-149, 1995
10. Rigas JR, Francis PA, Miller VA, Tong WP, Roistacher N, Kris MG, Orazem JP, Young CW, Warrell RP Jr: Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule. Cancer Chemother Pharmacol 35(6):483-488, 1995
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92(3):205-216, 2000
12. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG: Superiority of oxaliplatin and fluorouracilleucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracilleucovorin: interim results of a phase III Trial. JCO 2059-2069, 2003
13. Toumigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22(2):229-237, 2004
14. Kim R, Ohi Y, Inoue H, Toge T: Expression and relationship between topoisomerase I and II alpha genes in tumor and normal tissues in esophageal, gastric and colon cancers. Anticancer Res. 19(6B):5393-5398, 1999